Addendum
Icosapent ethyl (cardiovascular risk reduction) - Addendum to Commission A21-113
Report documents
-
Addendum
Icosapent ethyl (cardiovascular risk reduction) - Addendum to Commission A21-113
Dossier assessment
Indication:
Reduction of the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥ 150 mg/dL [≥ 1.7 mmol/L]) as well as
- established cardiovascular disease or
- diabetes mellitus and at least one further cardiovascular risk factor
Additional information
Federal Joint Committee (G-BA)
2022-02-18 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A22-03
- Commission
- Commission awarded on 11.01.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Icosapent ethyl (hypertriglyceridaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed